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Abstract: Review on NCR2, with data on DNA/RNA, on the protein encoded and where the gene is implicated. 
 
Identity 
Other names: CD336, LY95, NK-p44, NKP44, 
dJ149M18.1 
HGNC (Hugo): NCR2 
Location: 6p21.1 
Local order: NKp44 is centromeric to the Major 
Histocompatibility Complex on Chromosome 6 in a 
cluster of single immunoglobulin variable domain 
receptors.  
NKp44 is centromeric by 49071 bp to triggering 
receptor expressed on myeloid cells (Trem-1), located 
on the negative strand, and telomeric to forkhead box 
p4 by 195539 bp. 
Note 
NKp44 is a transmembrane glycoprotein of the 
Immunoglobulin (Ig) superfamily expressed on the 
surface of IL-2 and IL-15 activated Natural Killer  
(NK) cells (Cantoni et al., 1999; de Rham et al., 2007; 
Rosental et al., 2011; Horton et al., 2013). NKp44, 
NKp30, and NKp46 make up the Natural Cytotoxicity 
receptors of the NK cell and cooperate with each other 
for optimal recognition and elimination of target cells 
(Augugliaro et al., 2003). NKp44 can either activate or 
inhibit NK cell effector function through recognition of 
separate ligands.  
NKp44 recognition of its unknown activating ligand 
facilitates signalling through Dap 12, resulting in 
release of cytotoxic agents, Tumor Necrosis Factor-α, 
and IFN-γ (Vitale et al., 1998). Recognition of cell 
surface Proliferating Cell Nuclear Antigen (PCNA) 
colocalizing with HLA I on the cell surface inhibits NK 
cell cytotoxicity and IFN-γ release (Rosental et al., 
2011; Horton et al., 2013).  
NKp44 expression is inhibited by IL-21 (de Rham et 
al., 2007). 
 
Three splice variants of NKp44. NKp44 is encoded on 5 exons (NM_004828.3). One splice variant contains an additional exon 
(NM_001199510.1), adding 35 amino acids resulting in a shift in the reading frame, truncating the cytoplasmic tail by 18 amino acids 
(Allcock et al., 2003). A second splice variant (NM_001199509.1) adds 12 amino acids, but maintains the reading frame with a 36 base 
pair extension on the 5' side of exon 4 (Allcock et al., 2003). 
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DNA/RNA 
Note 
NKp44 is located on chromosome 6, centromeric to the 
Major Histocompatibility Complex. It is located in a 
cluster of single immunoglobulin variable domain 
receptors including Trem-1 and Trem-2 (Allcock et al., 
2003). 
Description 
NKp44 gene spans 15098 bases located on positive 
strand of chromosome 6 from 41303528 to 41318625 
bp. NKp44 is centromeric to Trem-1, with its leader 
sequence nearest to Trem-1 on the telomeric side and 
its cytoplasmic domain encoded towards the 
centromere (Allcock et al., 2003). NKp44 is encoded in 
5 exons with one splice variant containing an extra 
exon (NM_001199510.1), adding 35 amino acids 
(Allcock et al., 2003). This addition alters the reading 
frame which truncates the cytoplasmic tail by 18 amino 
acids (Allcock et al., 2003). A second splice variant 
(NM_001199509.1) with an extra exon contains a 36 
base pair extension of exon 4 on the 5' side, adding 12 
amino acids, but maintaining the reading frame 
(Allcock et al., 2003). 
Transcription 
There are three transcript variants of NKp44. Isoform 1 
(NM_004828.3) encodes the longest isoform. Isoform 2 
(NM_001199509.1) encodes a frame shift due to an 
extra in-frame segment and an additional exon 
compared to isoform 1. This results in an additional 
internal segment and a shorter C-terminus. Isoform 3 
(NM001199510.1) has an additional exon with a 
shorter C-terminus similar to isoform 2. 
Protein 
Note 
NKp44 is a type I transmembrane protein belonging to 
the Ig Superfamily (Vitale et al., 1998; Cantoni et al., 
1999; Cantoni et al., 2003). Surface expression of the 
receptor and signalling physically requires the 
transmembrane accessory protein DAP12 which bears 
Immunoreceptor Tyrosine Activation Motifs (Cantoni 
et al., 1999). NKp44 activates NK cells through DAP12 
linked directly to Lysine 183 in the transmembrane 
domain (Campbell et al., 2004). NKp44 inhibits NK 
cells through a tyrosine-based inhibitory motif located 
in the cytoplasmic tail of the receptor (Rosental et al., 
2011). 
Description 
NKp44 has a molecular weight of 44 kDa and consists 
of a 169 amino acid extracellular domain followed by 
23 and 63 amino acid sequences in the transmembrane 
and cytoplasmic tail domains respectively (Cantoni et 
al., 1999; Cantoni et al., 2003). A 55 amino acid 
domain connects the extracellular Ig domain to the  
transmembrane segment and has 13 predicted O-
glycosylation sites and a single N-glycosylation site 
(Cantoni et al., 1999; Cantoni et al., 2003). 
Crystallography of the receptor demonstrates a surface 
groove made by two facing β hairpin loops extending 
from the Ig fold core stabilized by a disulfide bridge 
between Cystine 37 and Cystine 45 (Cantoni et al., 
2003). The Ig domain contains an arrangement of 
positively charged residues at the groove surface, 
suggesting NKp44 ligands are anionic (Cantoni et al., 
2003).  
The groove appears wide enough to host a sialic acid or 
an elongated branched ligand. The cytoplasmic tail of 
NKp44 also contains a tyrosine sequence resembling a 
tyrosine-based inhibitory motif (Cantoni et al., 1999; 
Campbell et al., 2004). This motif is functional and 
inhibits the release of cytotoxic agents and IFN-γ 
(Rosental et al., 2011). 
Expression 
NKp44 is expressed on IL-2 and IL-15 activated NK 
Cells and NK cells in the decidua (Cantoni et al., 1999; 
de Rham et al., 2007; Manaster and Mandelboim, 
2010). The receptor is also expressed on isolated 
polyclonal γδ T cells when cultured for 2 weeks in IL-
15 and IL-2 (Cantoni et al., 1999; von Lilienfeld-Toal 
et al., 2006; Hudspeth et al., 2013). Natural Interferon-
producing cells located in the T-cell zone in lymph 
nodes draining a site of viral infection are reported to 
express NKp44, believed to be induced by IL-3 from 
local memory CD8 T cells (Fuchs et al., 2005). NKp44 
is also induced in TCR αβ intestinal intraepithelial 
lymphocytes by IL-15 (Meresse et al., 2004). Cytolytic 
T cells isolated from cord blood express NKp44 when 
induced with IL-2 or IL-15 (Tang et al., 2008). Finally 
NKp44 is expressed on a subset of cells located in 
human tonsils, similar to lymphoid tissue induce cells, 
which produce IL-22 and express Rorγt (Fuchs et al., 
2005; Cella et al., 2009). 
Localisation 
NKp44 is a type I transmembrane protein expressed on 
the surface of IL-2 activated NK cells and induced in 
γδ T cells by IL-15 and IL-2 (Cantoni et al., 1999; von 
Lilienfeld-Toal et al., 2006; Hudspeth et al., 2013). 
Expression is also reported on the cell surface of 
natural interferon-producing cells exposed to IL-3 
(Fuchs et al., 2005). 
Function 
NKp44 may functions as either an activating or 
inhibitory receptor on the surface of the NK cell. The 
identities of activating ligands are currently unknown, 
but bind NKp44 to induce activating signals through 
Dap12 (Vitale et al., 1998; Cantoni et al., 1999; 
Campbell et al., 2004). NKp44 inhibits NK cell 
function through recognition of cell surface exosomal 
PCNA which colocalizes with HLA I (Rosental et al., 
2011; Horton et al., 2013). 
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Homology 
- NCR 2 Natural Cytotoxicity Trigger Receptor 2 [Pan 
troglodytes] NC_006473.3 
- NCR 2 Natural Cytotoxicity Trigger Receptor 2 
[Macaca mulatta] NC_007861.1 
- NCR 2 Natural Cytotoxicity Trigger Receptor 2 
[Canis lupus familiaris] NC_006594.3 
Mutations 
Note 
None identified. 
Implicated in 
Various cancers 
Note 
NKp44 is implicated in recognition of numerous types 
of cancer (neuralblastoma, choriocarcinoma, 
pancreatic, breast, lung adenocarcinoma, colon, cervix, 
hepatocellular carcinoma, Burkitt lymphoma, diffuse B 
cell lymphoma, prostate) (Sivori et al., 2000a; Sivori et 
al., 2000b; Byrd et al., 2007; Rosental et al., 2011; 
Horton et al., 2013). Ligands for NKp44 appear to be 
cell cycle regulated, with down regulation of 
expression during mitosis (Byrd et al., 2007). 
Recognition of tumor cells is partially mediated 
through charged based binding of NKp44 with heparin 
sulfate proteoglycans (HSPG) on the surface of tumor 
cells (Hershkovitz et al., 2007). Specifically, the 2-O-
sulfation of iduronic acid and N-acetylation of 
glucosamine on HSPGs are important for interaction 
with NKp44 (Hecht et al., 2009). Glycans containing 
α2,6-N¬-acetylneuraminic acid are also recognized on 
the surface of cancer cells by NKp44 (Ito et al., 2012). 
HSPGs are believed to be a coligand for NKp44 and 
the other NCRs, potentially facilitating binding with 
other cellular ligands. Recognition of HSPG only 
evokes IFN-γ release by NK cells, not cellular 
cytotoxicity (Hershkovitz et al., 2007). 
Tumor escape of immunosurveillance 
Note 
Tumors employ numerous mechanisms to avoid killing 
by NK cells. By engaging NKp44, as well as the other 
NCRs, tumors can induce NK cell death via up 
regulation of Fas Ligand in the NK cell, inducing Fas 
mediated apoptosis (Poggi et al., 2005). NKp44 surface 
expression can be down regulated by soluble MHC 
Class I chain-related molecules shed by colorectal 
tumors or by indoleamine 2,3-dioxygenase and 
prostaglandin E2 released by melanoma cells 
(Doubrovina et al., 2003; Pietra et al., 2012). 
Mesenchymal stem cells also release indoleamine 2,3-
dioxygenase and prostaglandin E2 which inhibit 
NKp44 induction in the tumor microenvironment, but 
may also be harnessed as a therapeutic approach to 
inhibit Graft-versus-host or autoimmune disease 
(Spaggiari et al., 2008). Tumors may also down 
regulate NKp44 ligand expression to escape NK cell 
killing, as is the case with acute myeloid leukemia 
(AML) (Nowbakht et al., 2005). In the case of normal 
myelonocytic differentiation of bone marrow cells, a 
ligand for NKp44 is expressed upon loss of the CD34 
hematopoietic marker and acquisition of CD33 and 
CD14 myeloid markers (Nowbakht et al., 2005). 
Ligand expression if further increased by the presence 
of IFN-γ (Nowbakht et al., 2005). Yet in AML, ligand 
expression is absent, possibly contributing to disease 
manifestation. Finally, tumor cells may also induce 
expression of exosomal PCNA when physically 
contacted by NKp44 expressing NK cells to inhibit NK 
cell effector function (Rosental et al., 2011). 
Viral infection 
Note 
NKp44 recognizes α2,6-N¬-acetylneuraminic acid of 
hemagglutinin of Influenza and Sendai viruses and 
hemagglutinin-neuraminidase of the Newcastle disease 
virus, requiring sialyation of the receptor (Arnon et al., 
2001; Jarahian et al., 2009; Ito et al., 2012). Binding of 
NKp44 to hemagglutinin enables lysis of viral infected 
cells. Specifically, NKp44 recognizes hemagglutinins 
from H5-type influenza virus strains (Ho et al., 2008). 
Two flaviviruses, Dengue and West Nile, are directly 
recognized by NKp44. Envelope proteins of these 
viruses, in particular domain III of West Nile, directly 
bind to NKp44, increasing lysis of infected cells and 
NK cell IFN-γ release (Hershkovitz et al., 2009). 
NKp44 is also implicated in recognizing a ligand 
expressed on cells infected with Vaccina virus 
(Chisholm and Reyburn, 2006). Viruses have also 
evolved immune escape mechanisms by down 
regulating expression of the ligand for NKp44. In the 
case of Kaposi's sarcoma-associated herpes virus, the 
extracellular ligand expression is reduced during de 
novo infection. Interestingly, during lytic infection, 
only surface levels of the NKp44 ligand are reduced as 
overall cellular levels are unchanged, indicating a 
defect in cellular trafficking (Madrid and Ganem, 
2012). Also, while the NKp44 ligand is typically 
located outside of the nucleus, during lytic infection the 
ligand is found localizing to the nucleus (Madrid and 
Ganem, 2012). This localization is concurrent with a 
burst of lytic gene expression, mainly consisting of 
immune related genes (Madrid and Ganem, 2012). 
HIV 
Note 
A hallmark of HIV infection is the progressive 
depletion of CD4+ T cells via destruction of both 
uninfected CD4+ T cells and HIV-infected CD4+ T 
cells. In regards to NK cells, HIV modulates both the 
expression of NK cell receptors and their ligands. 
NKp44 is no exception as it is expressed at a lower 
surface density on in vitro activated NK cells from  
NCR2 (natural cytotoxicity triggering receptor 2) Horton N, et al. 
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HIV-1 patients compared to healthy controls, resulting 
in decreased killing of various tumor target cells (De 
Maria et al., 2003; Mavilio et al., 2003; Fogli et al., 
2004). HIV also modulates NK cell receptor ligand 
expression. NKp44 cellular ligand (NKp44L) is 
expressed on uninfected CD4+ T cells during an HIV 
infection, correlating with the loss of CD4+ T cells and 
increase of viral load (Vieillard et al., 2005). NKp44L 
is only expressed in high amounts on uninfected CD4+ 
T cells and is not responsible for inducing NK lysis of 
HIV-infected cells (Ward et al., 2007). To avoid NK 
killing of HIV infected CD4+ T cells, the Nef protein of 
HIV-1 retains NKp44L intracellularly, preventing cell 
surface expression and interaction with NKp44 
(Fausther-Bovendo et al., 2009). Studies by Vieillard et 
al. have shown a highly conserved 3S peptide motif of 
the HIV-1 gp41 protein is involved in the induction of 
NKp44L on the surface of uninfected CD4+ T cells. An 
envelope protein of the HIV virus, gp41 is vital for 
viral entry into target cells (Vieillard et al., 2005). The 
3S peptide of gp41 binds to its receptor gC1qR, a 
receptor for the globular domain of complement 
component 1q, on CD4+ T cells (Fausther-Bovendo et 
al., 2010). Binding of the 3S motif to this receptor 
activates a signaling cascade involving PI3K, NADPH-
oxidase, Rho-A, and TC10 (Fausther-Bovendo et al., 
2010). NKp44L is translocated from the cytoplasm to 
the plasma membrane and is expressed on the cell 
surface, where it can bind to NKp44 of activated NK 
cells. NKp44L+ expressing CD4+ T cells are more 
susceptible to lysis by activated NK cells (Vieillard et 
al., 2005). Understanding the role of NKp44L during 
HIV infection could help identify new therapeutic 
strategies to prevent the progressive loss of uninfected 
CD4+ T cells. Possible therapeutic strategies are to 
inhibit the expression of NKp44L by using an anti-
gp41 Ab or an anti-gC1qR Ab to block the 3S motif 
and gC1qR interaction (Vieillard et al., 2005; Fausther-
Bovendo et al., 2010). Anti-3S immunization has also 
proven efficacious in preliminary studies in macaques 
(Vieillard et al., 2008). 
Microbial infection 
Note 
Nkp44 is reported to directly bind to the surface of 
Mycobacterium and other related genera. After in vitro 
stimulation with Mycobacterium bovis bacillus 
Calmette-Guérin (BCG) for 3 to 4 days, CD56bright NK 
cells significantly increase NKp44 expression (Esin et 
al., 2008). The Mycobacterium genus, including the 
causative agent of tuberculosis, Mycobacterium 
tuberculosis, express a conserved NKp44 ligand while 
the mycobacterium related, Gram-positive Nocardia 
and Corynbacterium genera, also express a ligand (Esin 
et al., 2008; Esin et al., 2013). Interestingly, both 
Nocardia, Corynbacterium, and Mycobacterium genera 
express mycolic acids in their cell walls, which is 
lacking in other mycobacterium related species which  
do not express a ligand for NKp44 (Esin et al., 2008). 
Furthermore, the BCG NKp44 ligand was found to be 
resistant to trypsin degradation and stable at 80°C, 
indicating the ligand is most likely not a protein but a 
heat stable structural component of the cell wall (Esin 
et al., 2008). In a subsequent study, Esin et al. further 
proved NKp44 specifically binds mycolyl-
arabinogalactan-peptidoglycan, mycolic acid, and 
arabinogalactan found in the cell wall of 
Mycobacterium tuberculosis to maintain NK cell 
activation (Esin et al., 2013). Finally, Pseudomonas 
aeruginosa also express a ligand for NKp44 (Esin et al., 
2008). 
Formation of placenta 
Note 
Decidual NK cells (dNK) make up 50-90% of 
lymphocytes in the uterine mucosa during pregnancy 
and constitutively express NKp44 (Kopcow et al., 
2005; Hanna et al., 2006; Vacca et al., 2008). In close 
contact with fetal extravillous trophoblasts cells 
invading the maternal decidua, dNK cells exhibit 
reduced cytotoxicity but crucially produce Interleukin-
8, Interferon-inducible protein 10, Vascular Endothelial 
Growth Factor (VEGF), and Placental Growth Factor 
(PGF) in response to NKp44 triggering (Hanna et al., 
2006; Vacca et al., 2008).  
Trophoblast cells and maternal stromal cells of the 
decidua both express unidentified NKp44 ligands 
(Hanna et al., 2006; Vacca et al., 2008). This ligand 
may be PCNA as the protein is over expressed in 
trophoblast cells during the first trimester (Korgun et 
al., 2006).  
As an inhibitory ligand for NKp44, extracellular PCNA 
expression on trophoblast cells would help explain the 
diminished ability of dNK cells to lyse trophoblasts 
despite low levels of classical HLA I expression (Vacca 
et al., 2008). Invasion of trophoblast into decidua 
facilitates proper placentation and NK cells help govern 
how far trophoblasts infiltrate (Moffett and Loke, 
2006). dNK cells also help reorganize the spiral arteries 
to facilitate appropriate blood transfer between the 
mother and fetus at the placenta (Moffett and Loke, 
2006; Vacca et al., 2008).  
Alterations in dNK cells and invasion of fetal 
trophoblast cells are implicated in pregnancy 
complications, such as pre-eclampsia and tubal 
pregnancies (Moffett and Loke, 2006). Since fetal 
trophoblast and maternal decidual cells express a 
NKp44 ligand, this receptor constitutively expressed on 
dNK cell plays a crucial role in proper development of 
the placenta in pregnancy that requires further study. 
Spontaneous abortion 
Note 
NKp44 expression is increased on CD56brightCD16- 
dNK cells in patients with spontaneous abortion, 
resulting in increased cytolytic activity of these NK 
cells (Zhang et al., 2008). 
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Crohn's disease and ankylosing 
spondylitis 
Note 
NKp44+ NK cells (CD3-CD56+NKp44+NKp46-
RORChighCD122-CD127+) in the intestinal lamina 
propria are significantly reduced in inflamed mucosa of 
patients with Crohn's Disease (CD) while IFN-γ 
producing NKp46+ NK cells (CD3-CD56+NKp44-
NKp46+RORCdullCD122+CD127-) are dramatically 
increased (Takayama et al., 2010). IL-22 is produced 
by NKp44+ NK cells, which is protective in the onset of 
murine colitis, and possibly implicated in human 
colitis. Thus the imbalance of the NKp44+/NKp46+ 
NK cell axis in the intestinal lamina propria may play a 
role in colitis onset (Takayama et al., 2010). Contrary 
to CD, NKp44+ NK cells are increased in the inflamed 
ileum of patients with Ankylosing Spondylitis (AS) 
(Ciccia et al., 2012). AS Patients over express IL-23 in 
the intestines which modulates IL-22 production by 
NKp44+IL-22+ NK cells (Ciccia et al., 2012). IL-22 
then promotes mucosal wound healing through 
increased mucin production by goblet cells. 
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